Results 91 to 100 of about 11,371 (259)
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, 2012 Combination with cabergoline may offer additional benefits to acromegalic patients on pegvisomant monotherapy. We evaluated the safety and efficacy profile of this combination and investigated the determinants of response. An observational, retrospective, cross-sectional study.
Amalia-Elisa Paniagua +8 more
openaire +5 more sources
Equine Veterinary Education, Volume 37, Issue 4, Page 202-209, April 2025.Summary Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are being used increasingly in equine practice. While there is emerging clinical evidence of the safety and efficacy of these drugs, there are currently no reports to document owner experiences with treatment.
Tania Sundra +4 more
wiley +1 more source
Advanced Science, Volume 12, Issue 12, March 27, 2025.The authors uncovered that targeting the constitutive androstane receptor (CAR) might decelerate the aging process. Employing models like C. elegans and mice, they determined that CAR agonists CITCO and TCPOBOP can extend both the lifespan and healthspan.
Jing Yu +12 more
wiley +1 more source
Dopamine receptor expression and function in corticotroph pituitary tumors [PDF]
, 2004 The role of dopamine agonist treatment in corticotroph pituitary tumors is controversial. The aim of this study was to evaluate D(2) receptor expression in 20 corticotroph pituitary tumors and to correlate it to the in vitro effect of ...
Annunziato, L. +10 more
core +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Macroprolactinoma are rare in childhood, especially in the first decade. A 9-year-old girl presented with headache, vomiting, and decreased vision for 8 months. A diagnosis of macroprolactinoma was made following documentation of elevated serum prolactin
Chitra Selvan +4 more
doaj +1 more source
AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]
, 2019 Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A. +2 more
core
Diabetes mellitus secondary to Cushing's disease [PDF]
, 2018 Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism.
Barbot, Mattia +2 more
core +2 more sources
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]
, 2016 Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea +3 more
core +2 more sources
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients [PDF]
Obstetrical & Gynecological Survey, 1999 Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the ...
Verhelst, Johan +14 more
openaire +5 more sources
Fetal death: Expert consensus of the French College of Obstetricians and Gynecologists
International Journal of Gynecology &Obstetrics, Volume 168, Issue 3, Page 999-1008, March 2025.Abstract Fetal death is defined as the spontaneous cessation of cardiac activity after 14 weeks gestational age (GA). Regarding prevention of fetal death in the general population, it is not recommended to counsel or prescribe rest, aspirin, vitamin A, vitamin D, or micronutrient supplementation; systematically look for nuchal cord during prenatal ...
Charles Garabedian +19 more
wiley +1 more source